OCT 28, 2020 7:00 AM PDT

Guiding pancreatic cancer therapy by individualized epigenetics

Sponsored by: Agilent
C.E. Credits: P.A.C.E. CE Florida CE
Speakers

Abstract
Date:  October 28, 2020
Time: 7:00am (PDT),  10:00am (EDT)
 
Although chemotherapy remains the mainstay of systemic therapy, a large number of cancer patients fail to respond to it. About half of surgically resected pancreatic ductal adenocarcinoma (PDAC) patients relapse within a year despite adjuvant chemotherapy. By investigating tumor-cell-intrinsic chromatin accessibility patterns of resected PDAC, we discovered a signature of 1092 chromatin loci displaying differential accessibility between patients with disease free survival (DFS) < 1 year and patients with DFS > 1 year. Based on this signature, we developed “ATAC-array” – the only microarray that reads chromatin accessibility – a convenient platform obviating the time and cost of Next Generation Sequencing. We also identified HNF1b, a transcription factor displaying differential nuclear localization between patients with short vs. long DFS. Combining these two simple methodologies, ATAC-array “Prognosis Score” and HNF1b nuclear localization, we have developed an algorithm which we call PancEpistemeDx, and stratified PDAC patients into prognostic groups with up to four-fold differences in DFS. Whether adverse patterns of chromatin accessibility might assist in the selection of PDAC patients for epigenetic “reprogramming” therapy remains to be determined, but our stratification provides a simple and clinically achievable prediction of favorable vs unfavorable epigenetic states in PDAC. Episteme Prognostics aims to 1) optimize PancEpistemeDx for routine clinical use and expand it to all stages of pancreatic cancer, and 2) develop companion diagnostics (CDx) for epigenetic drugs. We sit at the dawn of the epigenetic drug discovery era, the FDA has already approved 9 epigenetic drugs, and currently, 138 clinical trials on epigenetic drugs are registered by 31 different pharmaceutical companies. Our technology can support therapeutic decision-making in pancreatic cancer clinics, as well as can support clinical trials on epigenetic drug discovery for pharma companies.
 
Learning Objectives:
  • How epigenetics adds an important layer of information on top of genetic mutations to inform cancer research
  • How microarray analysis may reveal innovative approaches to deliver companion diagnostics in the future
  • How epigenetics may be used as a novel approach to drug discovery
 
For Research Use Only. Not for use in diagnostic procedures.
 
 
Webinars will be available for unlimited on-demand viewing after live event.
 
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
MAR 18, 2021 8:00 AM PDT
C.E. CREDITS
MAR 18, 2021 8:00 AM PDT
DATE: March 18, 2021 TIME: 8:00am PDT Sequencing of bulk cells, single cells, and nuclei is opening doors in the understanding of complex biological processes....
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
Loading Comments...
Show Resources